Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Monday 07 March, 2022

Omega Diagnostics Gp

Result of General Meeting

RNS Number : 9106D
Omega Diagnostics Group PLC
07 March 2022
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Result of General Meeting

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, announces that at the General Meeting held earlier today, resolution 1 (an ordinary resolution) passed, but resolution 2 (a special resolution) was not passed.

 

As a result, the Placing, Subscription and Open Offer will not take place. The Group is therefore not funded to pursue its growth strategy as set out in the Circular. The Directors will now need to reassess the strategy, reflecting on alternative options for funding for the Company and will update the market in due course.

 

A breakdown of the voting results for each resolution is provided on the Company's website here:

https://www.omegadx.com/Investor-Relations/Corporate-Information  

 

Jag Grewal, Chief Executive Officer, of Omega Diagnostics said: "The Board is encouraged that resolution 1, increasing the Directors' authority to allot shares, was approved by shareholders and notes the views of some retail shareholders with regards to resolution 2 and their pre-emption rights. Accordingly, the fundraise will not proceed and the Company will look at other strategic and funding options."

 

 

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 11 February 2022.

 

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

 

 

 

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

 

Alice Lane/ Charlotte Sutcliffe (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

       

 

 

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMEDLFBLXLXBBD

a d v e r t i s e m e n t